Sobi exceeds in 2Q; takeover speculation to continue?
This article was originally published in Scrip
Executive Summary
Swedish Orphan Biovirtum (Sobi) has surpassed expectations for the second quarter of 2015 and raised its guidance for the rest of the year – again leaving the company looking like a viable acquisition target.